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Abstract 
Objective: To assess bone mineral density in patients with cystic fibrosis (CF), and to 
correlate it with possible intervening variables.
Methods: Children and adolescents diagnosed with CF, aged 6 to 18 years, followed at 
the outpatient clinic were included in the study. First, demographic data were collected 
and, subsequently, patients underwent a spirometric test. All patients answered the 
Cystic Fibrosis Quality of Life Questionnaire (CFQ) and underwent the six-minute walk 
test (6MWT) and bone densitometry (DXA).
Results: A total of 25 CF patients were included, of which 56% were males. The mean age 
was 12.3±3.4 years; mean height was 149.2±14.4 cm; and mean weight was 44.4±13.9 
kg. Most results on pulmonary function and bone mineral density (BMD) were within 
normal limits. The mean forced expiratory volume in one second (FEV1) was 92.5±23.6 
(% of predicted), mean forced vital capacity (FVC) was 104.4±21.3 (% of predicted), and 
mean BMD z-score was 0.1±1.0. BMD was moderately correlated with FEV1 (r = 0.43, p 
= 0.03) and FVC (r = 0.57, p = 0.003). Regarding chronological age and age at diagnosis, 
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Densidade mineral óssea, função pulmonar, idade cronológica e idade de diagnóstico 
em crianças e adolescentes com fibrose cística
Resumo 
Objetivo: Avaliar a densidade mineral óssea de pacientes com fibrose cística (FC) e 
correlacioná-la com possíveis variáveis intervenientes. 
Métodos: Foram incluídos crianças e adolescentes com diagnóstico clínico de FC, idade 
entre seis e dezoito anos, e em acompanhamento ambulatorial. Primeiramente, foram 
coletados os dados demográficos, para posterior realização do teste espirométrico. 
Todos os pacientes responderam ao questionário de qualidade de vida em FC (QFC) e 
realizaram o teste de caminhada dos seis minutos (TC6) e o exame de densitometria 
óssea (DXA). 
Resultados: Foram incluídos 25 pacientes fibrocísticos, sendo 56% do sexo masculino. 
A média de idade foi de 12,3 ± 3,4 anos, altura de 149,2 ± 14,4 cm e peso de 44,4 
± 13,9 kg. A maioria dos dados de função pulmonar e de densidade mineral óssea 
(DMO) encontrou-se dentro dos limites de normalidade. A média do volume expiratório 
forçado no primeiro segundo (VEF1) foi de 92,5 ± 23,6 (% do previsto), capacidade vital 
forçada (CVF) de 104,4 ± 21,3 (% do previsto) e o escore z da DMO de 0,1 ± 1,0. A DMO 
correlacionou-se de forma moderada com o VEF1 (r = 0,43; p = 0,03) e com a CVF (r = 
0,57; p = 0,003). Em relação à idade cronológica e à idade de diagnóstico, também foi 
encontrada uma correlação moderada e inversa (r = −0,55; p = 0,004 / r = −0,57; p = 
0,003, respectivamente). Entretanto, não foram encontradas correlações significativas 
com os dados do QFC, TC6 e índice de massa corporal. 
Conclusão: A maioria dos pacientes avaliados apresenta DMO dentro dos limites de 
normalidade e possui correlação positiva com a função pulmonar e negativa com a idade 
cronológica e a idade de diagnóstico.
© 2013 Sociedade Brasileira de Pediatria. Publicado por Elsevier Editora Ltda.  
Introduction
With improved treatment and better understanding of 
cystic fibrosis (CF), the life expectancy of these patients 
has increased.1 However, as the age of survival increases, 
other complications start to become apparent such as liver 
disease, diabetes mellitus, and low bone mineral density.2 
Of these, the last is the most emergent problem, due to 
increased risk of fractures and possible impact on these 
patients’ quality of life.3 
Many studies have shown that there may be a decrease 
in bone mineral density (BMD) in children and young 
adults,4-6 reporting that osteopenia can be found in 28% 
to 47% of this population, and osteoporosis in 20% to 34%.7 
As a whole, bone disease in CF patients probably appears 
or worsens around puberty and continues deteriorating 
during adulthood with a variety of risk factors. The use 
of corticosteroids, hypogonadism, decreased physical 
activity, decreased muscle mass, growth alterations, 
malnutrition, low absorption of calcium, vitamins D 
and K deficiency, and chronic pulmonary infection 
could be involved in the pathogenesis.8,9 Moreover, 
puberty is a critical period for bone mineralization 
and requires special care so that optimum peak bone 
mass can be attained.10 Thus, BMD gains are decreased 
even in young children with mild CF, suggesting the 
role of other pathophysiological mechanisms, such as 
the negative impact of cystic fibrosis transmembrane 
conductance regulator (CFTR) protein dysfunction on 
bone formation.11 
a moderate and inverse correlation was also found (r = −0.55, p = 0.004 ; r = −0.57, p = 
0.003, respectively). However, no significant correlations were found with the data from 
CFQ, 6MWT, and body mass index. 
Conclusion: Most patients had BMD within normal limits and presented a positive 
correlation with pulmonary function, as well as a negative correlation with chronological 
age and age at diagnosis.
© 2013 Sociedade Brasileira de Pediatria. Published by Elsevier Editora Ltda.  
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BMD also appears to be associated with decreased lung 
function and lower exercise capacity.12 Thus, effective 
strategic measures are necessary to optimize bone health, 
such as BMD monitoring by bone densitometry (DXA), and 
preventive care from infancy through adolescence.13 
However, there is little evidence of these associations 
in the pediatric population, justifying studies that aim at 
a better understanding of the correlations between bone 
mass and intervening factors in children and adolescents 
with CF. Moreover, there is still little information on 
associations with quality of life indices and functional 
capacity in this age group, making it difficult to understand 
the influence of these parameters on BMD. 
Therefore, considering that decrease in BMD has been 
reported in the pediatric population and the absence 
of information on the associations of BMD with possible 
intervening variables in this population, particularly 
with exercise capacity and quality of life indices, this 
study aimed to evaluate BMD in children and adolescents 
with CF, and to correlate it with possible intervening 
variables. A better understanding of these associations in 
the pediatric population may help to establish the best 
conduct and early therapeutic interventions in patients 
with CF. 
Material and methods
This was a cross-sectional study, whose sample consisted 
of patients with clinical diagnosis of CF confirmed 
through the sweat test and/or genetic assessment, and 
followed at the CF clinic of the Hospital São Lucas of 
the Pontifícia Universidade Católica do Rio Grande do 
Sul (PUCRS). The study sample was aged between 6 and 
18 years, had clinically stable disease, and had cognitive 
capacity to perform all procedures. Patients who failed 
to perform the lung function test or who were receiving 
systemic corticosteroids for more than 15 consecutive 
days were excluded. The research protocol was initiated 
only after approval by the Research Ethics Committee of 
PUCRS (CEP-PUCRS) under No. 09/04683, and an informed 
consent form was read and signed by patients and/or 
guardians. 
Firstly, data were collected regarding patient 
identification (name, medical record number, age, 
gender), weight, and height. Selected patients underwent 
interdisciplinary clinical assessment and subsequent 
pulmonary function test (spirometry) as routine outpatient 
care. The questionnaires for quality of life questionnaires 
were applied during the physical therapy team assessment 
and, at the end of the interdisciplinary clinical assessment, 
patients were referred for the six-minute walk test (6MWT) 
and DXA examination. 
Pulmonary function test
Assessment of pulmonary function was performed by 
spirometry using a KOKO spirometer (Louisville, CO, 
USA). The evaluated spirometric parameters included 
forced vital capacity (FVC), forced expiratory volume 
in one second (FEV1), Tiffeneau index (FEV1/FVC), and 
forced expiratory flow 25% and 75% of FVC (FEF25%-75%). 
Calibration was performed before each test session 
according to the manufacturer’s instructions. In order to 
perform the spirometric test, patients should not have 
had exacerbation of respiratory symptoms, nor have 
used short-acting bronchodilator 4 hours before the test 
or long-acting bronchodilator 12 hours before the test. 
A resting period of 5 to 10 minutes was required before 
each test. 
After instructions and previous training, the children 
were instructed to start the exam. The spirometric test 
was described in detail to each patient, with emphasis on 
maximum inspiration followed by a maximal fast expiration, 
following the criteria established by the American Thoracic 
Society (ATS).14 All spirometric tests were performed 
individually, in the standing position, with the use of a nose 
clip. For best presentation of results, spirometric values 
were expressed in absolute values and percentages of the 
predicted values.15 
Bone densitometry
DXA for the assessment of bone mineral content was 
performed by dual-energy X-ray absorptiometry of the 
lumbar column segment (L1 to L4) in a Hologic Discovery 
Wi DXA scanner. Bone mineral content (g) (BMC) and bone 
mineral density (g/cm²) were evaluated. To undergo DXA, 
the participants were advised to wear light clothing to 
prevent absorption by any material that could create an 
artifact. Thus, for acquisition of lumbar spine images, the 
patient was placed in the supine position on the examination 
table with legs supported by a cushion, forming an angle 
of 90° at the coxofemoral joints and 90° at the knees, and 
asked to remain still, without the need for sedation. The 
examination lasted approximately 2 minutes. The diagnosis 
of BMD was attained through standardized results using the 
z-score and the classification according to the International 
Society for Clinical Densitometry, in which low BMD occurs 
when z-score is #< −2, adjusted for age, gender, and 
height.16
Six-minute walking test
The 6MWT was performed according to the guidelines of the 
American Thoracic Society (ATS).17 As in the lung function 
tests, patients remained at rest for at least 30 minutes 
before starting the test. The parameters evaluated pre-and 
post-test included heart rate (HR) and oxygen saturation 
(SpO2) using a pulse oximeter (PalmSAT 2500, Nonin Medical 
– Plymouth, Minnesota, USA), blood pressure (CE0050, 
Tycos/Welch Allyn – Skaneateles Falls, New York, USA), 
respiratory rate (RR) (counted as chest wall excursions per 
minute), and score in the modified Borg scale to measure 
the perceived intensity of dyspnea. 
Patients were instructed to walk as fast as possible 
without running, being allowed to slow down, stop, or 
rest, if necessary. Thus, they were instructed to walk as 
far as possible for six minutes in a 30-meter long enclosed 
corridor with a flat and hard surface, marked at every 
meter. The child received the stimuli recommended by 
ATS at every minute. At the end of the six minutes, the 
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child was requested to stop at that exact place, so that 
the researcher could collect the data. The criteria for 
test discontinuation were manifestations of fatigue and 
intense dyspnea by the participant, SpO2 < 80%, or refusal 
to continue the test. Distance was calculated by counting 
the total number of laps performed at the end of the test 
and expressed in meters. The normalization of the walked 
distance was performed using reference equations and 
expressed by z-score.18,19 
Cystic Fibrosis Quality of Life Questionnaire
The quality of life assessment was performed using 
the Cystic Fibrosis Quality of Life Questionnaire (CFQ), 
translated and validated to be used in Portuguese.20 The 
CFQ contains 35 questions for the age groups of 6 to 13 
years, 50 questions for ages older than 14, and 44 questions 
for the parents. This instrument covers nine domains of 
quality of life, three symptom scales, and one item related 
to health perception: physical, body image, emotional, 
social/school, social role, vitality, nutrition, treatments, 
digestive, respiratory, weight, and health factors. The 
answers to each question are quantified and can reach a 
maximum of 100 points; the higher the final score, the 
better the quality of life. 
Statistical analysis 
Data normality was assessed using the Shapiro-Wilk’s test. 
For all variables with normal distribution, data were shown 
as mean and standard deviation. For the CFQ results, which 
showed some domains with asymmetric distribution, data 
were expressed as median and range. Data on BMD and on 
6MWT were expressed as z-scores, and spirometry results 
were shown as percentage of predicted value. Pearson’s 
correlation test or Spearman’s test were used to assess 
possible correlations of intervening variables with BMD, 
according to their distribution. All data processing and 
analyses were performed using the Statistical Package for 
Social Sciences (SPSS) version 18.0 (SPSS Inc. – USA). In 
all cases, differences were considered significant when p 
< 0.05. 
Results
A total of 25 patients with CF were included, with a 
mean age of 12.3±3.4 years, of which 56% were males. 
The sample characterization with anthropometric data, 
pulmonary function, and BMD are shown in Table 1. Most 
patients (84%) had pancreatic failure and needed enzyme 
replacement therapy. Regarding the classification of BMD 
z-score in this sample, no participant showed z-score 
below the normal range (-2), 11 (44%) had values between 
−1 and zero, two (8%) presented values between -1 and 
-2, and 12 (48%) had values above normal (higher than 
zero). As for the CFQ evaluation, scores above 70 were 
obtained for all assessed domains, except for the weight 
and vitality domains, which presented scores of 61.1 and 
66.7, respectively. The data are shown in Table 2 and, in 
general, indicate that the assessed children were within 
the normal range. 
When correlating FEV1 data and z-score values obtained 
in the DXA test, a moderate correlation coefficient was 
observed (r = 0.43, p = 0.03). When FVC data were 
analyzed with the BMD z-score values, a significant result 
was obtained (p = 0.003) with a correlation coefficient 
of 0.57, demonstrating that the better lung function, 
the better the bone density (Fig. 1). When analyzing the 
results of age at diagnosis with BMD z-score, significant 
correlation was found, with an inverse and moderate 
correlation coefficient (r = −0.57, p = 0.003), showing 
that the older the age at diagnosis of CF, the lower 
the BMD values. Likewise, age showed a significant 
inverse and moderate correlation (r = −0.55, p = 0.004), 
indicating that as the age increases, bone density 
decreases (Fig. 2). 
Conversely, data obtained through the CFQ in its specific 
domains showed no significant correlations with the z-score 
values of BMD in either case. Moreover, there was no 
significant correlation between BMD and distance walk in 
the 6MWT, nor with the calculated BMI values. 
Discussion
The results of the present study showed that most 
assessed patients had BMD values within the normal range; 
only two patients (z-score between −1 and −2) would 
have treatment indication according to the management 
recommendations for CF patients.21 In addition, they 
presented a positive correlation with lung function and 
an inverse correlation with chronological age and age 
at diagnosis. The findings of normal BMD in this study 
may be attributed to the fact that patients showed 
Table 1 Characteristics of the study sample.
Assessed variables 
Age (years) 12.3±3.4
Gender
Male 56%
Anthropometric data
Weight (kg) 44.4±13.9
Height (cm) 149.2±14.4
BMI (absolute)  19.5±3.3
BMI (percentage) 56.7±29.4
Pulmonary function (% of predicted)
FEV1 92.5±23.6
FVC 104.4±21.3
FEF25%-75% 79.8±33.2
Bone mineral densitometry (lumbar column)
BMC (g) 33.7±13.6
BMD (g/cm2) 0.7±0.1
z-score 0.1±1.0
BMC, bone mineral content; BMD, bone mineral density; BMI, 
body mass index; FEF25%-75%, forced expiratory flow at 25%-75% 
of forced vital capacity; FEV1, forced expiratory volume in one 
second; FVC, forced vital capacity.
Results shown as mean and standard deviation. 
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young mean age and also mild pulmonary impairment.22,23 
Previous studies also reported normal BMD values, and 
attributed these findings mainly to the preservation of 
nutritional status and low pulmonary impairment. However, 
several studies6,9,24 reported BMD deficiency in children and 
linked this decrease to nutritional impairment, number of 
hospitalizations, worse lung function, gonadal dysfunction, 
and treatment with steroids. 
Table 2 Quality of life assessment through the Cystic Fibrosis Quality of Life Questionnaire and correlation with bone mineral 
density.
Assessed domains  Mean±SD Median (range) Correlation with BMD (r) p-value
CFQ physical 77.8±13.9 77.8 (14.0-100.0)  −0.26 0.19
CFQ food 84.9±18.1 88.9 (18.1-100.0) −0.22* 0.28
CFQ treatment  81.8±19.5 88.9 (19.0-100.0) 0.08* 0.67
CFQ respiratory 75.6±18.6 75.6 (19.0-100.0) 0.12 0.54
CFQ role 90.3±12.3 91.7 (12.3-100.0) 0.66 0.15
CFQ vitality 66.7±22.4 62.5 (22.4-100.0) 0.43 0.39
CFQ emotional 80.3±13.6 86.7 (13.6-100.0) 0.91 0.67
CFQ social 72.0±15.6 71.4 (16.0-95.0) −0.19 0.35
CFQ body 85.8±17.1 88.9 (17.1-100.0) 0.22 0.28
CFQ health 73.2±26.2 77.8 (22.2-100.0) −0.54 0.20
CFQ weight 61.1±32.8 66.7 (0.00-100.0) 0.39 0.43
CFQ digestion 86.7±16.0 100.0 (16.0-100.0) −0.20* 0.92
BMD, bone mineral density; CFQ, Cystic Fibrosis Quality of Life Questionnaire; SD, standard deviation.
*Spearman correlation. Pearson’s correlation was used in the domains that are not indicated.
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Figure 1 Correlation between bone mineral density (BMD) z-
score and pulmonary function: FEV1 (forced expiratory volume 
in one second) in the upper chart and FVC (forced vital capaci-
ty) in the lower chart.
Figure 2 Correlation between bone mineral density (BMD) z-
score and chronological age (years) of patients evaluated in the 
upper chart and the age at diagnosis (years) in the lower 
chart. 
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These conflicting results appear to be related, at 
least in part, to differences in the characteristics of the 
studied patients and other intrinsic factors, such as those 
mentioned above. Moreover, differently from what occurs 
in the pediatric population, evidence of decreased bone 
mass in adults appears to be more present and to have 
been increasing, due to increased patient survival.4,12 
As expected, the results of lung function demonstrated 
a positive correlation between FVC and FEV1, with z-score 
values obtained from DXA examination, indicating that 
the worse the lung function, the lower the BMD indices. 
These results are in agreement with several authors 
who demonstrated FEV1 as a robust marker of lung 
disease severity, establishing a direct association with bone 
mass at all ages.12,13 Previous studies have demonstrated 
that impaired lung function is associated with increased 
presence of inflammatory mediators, leading to an impact 
of cytokines and interleukins on the mineralization of bone 
content, as there is increased bone resorption in periods of 
pulmonary exacerbation.7,25 
Unlike healthy children and adolescents, who present 
an increase in bone mass with increasing age, patients 
with CF may have a reduction in BMD.13 The results of the 
present study are consistent with these findings, showing 
that chronological age has an inverse correlation with bone 
density, indicating that as age increases, bone density 
decreases, emphasizing the importance of following these 
patients as they enter adolescence and adulthood. Studies 
in healthy populations have shown that healthy children 
have a constant gain in bone mass, extending from birth 
until they reach a peak in late adolescence or early 
adulthood. Thus, the higher the bone mass gained during 
childhood and adolescence, the lower the likelihood of 
fractures.26,27 
However, delayed puberty in CF patients may play an 
important role in peak bone mass, leading to reduced 
bone mineral content and to an increased risk of fractures 
in these patients.28 In this regard, some studies have 
shown that CFTR can directly modulate the reproductive 
endocrine axis, causing some puberty delays to be a direct 
consequence of the alteration in this protein function, as 
there can be alterations in the hypothalamic-pituitary-
gonadal axis.13 
Furthermore, the present study also showed an inverse 
correlation with age at diagnosis, showing that the older 
the age at which the diagnosis is made, the lower the bone 
density values, which demonstrates the importance of 
neonatal screening and of early diagnosis that would enable 
the rapid inclusion of these patients in referral centers for 
disease treatment and monitoring. 
To the authors’ knowledge, this is the first study in the 
pediatric population that evaluated the association between 
BMD and specific domains of the CFQ questionnaire. 
However, there were no significant correlations with any 
of the specific domains of the questionnaire. The results 
indicate a healthy perception by patients in most domains 
assessed. Quittner et al.,29 in their CFQ validation study, 
showed that the scores obtained in the different domains 
were positively correlated with lung function, indicating 
that the healthiest children had the highest scores in the 
CFQ. 
The slightly altered pulmonary function and BMD within 
the normal range observed in the present patients could be 
related to this absence of correlation. Moreover, there was 
no specific correlation with the physical activity domain 
of the questionnaire, or with the distance walked in the 
6MWT. There are no studies in the pediatric population that 
have correlated BMD with exercise capacity, both through 
the 6MWT or VO2max. Conversely, studies
12,30 conducted in 
the adult population showed a positive correlation with 
exercise capacity through submaximal and maximal tests, 
indicating that as the exercise capacity increases, the 
greater are the values of BMD.
The assessment of physical fitness through maximum 
tests could better reflect the aerobic fitness of a group 
of patients that show little involvement in comparison 
to submaximal tests, and could justify, in part, the 
lack of correlation with BMD in the assessed children 
and adolescents, constituting a limitation of this study. 
Furthermore, the evaluation of a sample with only 25 
patients, most with low pulmonary involvement and good 
nutritional status, can also be additional limiting factors. 
Future studies evaluating children with more compromised 
lung function and worse nutritional status could contribute 
to a greater knowledge on the subject. 
In conclusion, the results of the present study demonstrate 
that most patients have BMD within normal limits and that 
there is a positive correlation with lung function, and 
an inverse correlation with chronological age and age at 
diagnosis. A better understanding of the associations and 
of the evolution of bone health is of clinical and scientific 
relevance for the treatment and monitoring of children and 
adolescents with cystic fibrosis. 
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